

#### Publishable Summary

This quarterly report provides an overview of the project progress within the AMYPAD Prognostic and Natural History Study (WP4), with a focus on the period from July to September 2021.

In Q3 2021, COVID-19 did not directly affect sites, however during this period the recruitment and scan activity within the PNHS has been affected by the summer period during which some sites fully stopped their activities or continued at a slower pace. In addition, some additional issues across the sites affected the recruitment and scan activity. As a result, the recruitment and scan rates have decreased compared to Q2 2021. Only the number of scans (70) in July 2021 showed the same trend as the number of scans per month in the previous quarter.

Despite this in Q3 2021 most sites managed to close a big part of the gap between consented and scanned which was mainly caused by the COVID-19 crisis. Also, the global amendment v5.0 and local amendment V5.1 (Spain) has been approved in all countries.

In total, at the end of Q3 2021, AMYPAD PNHS had 1116 participants consented of which 1075 have already received a PET scan. Moving forward, the Q4 of 2021 should see an increase in the recruitment and scanning rate.

For more information: [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

